| EPF139 | Access to pre-exposure prophylaxis for HIV prevention among young people aged 15-24: a global policy review | E-poster | Policies regarding HIV services and programmes |
| EPF140 | The Australian Community Accord on Quality of Life for People with HIV ' an agenda for action to achieve good quality of life for people with HIV by 2030 | E-poster | Policies regarding HIV services and programmes |
| EPF141 | Monitoring the development of HIV policy at the sub-national level through Indonesia policy lab | E-poster | Policies regarding HIV services and programmes |
| EPF142 | Maternal HIV testing after first ANC visit: country guidelines and implementation | E-poster | Policies regarding HIV services and programmes |
| EPF143 | Accelerating the efforts to end HIV in the United States: the U.S. Department of Health and Human Services' priorities | E-poster | Policies addressing social and economic determinants of vulnerability |
| EPF144 | HIV and labour relations in Kenya: combatting discriminatory workplace practices | E-poster | Policies addressing HIV in the workplace and/or educational institutions |
| EPLBB06 | Suboptimal lopinavir exposure in infants 1-12 months on rifampicin treatment receiving double-dosed or semi-superboosted lopinavir/ritonavir; results from the EMPIRICAL trial | E-poster | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring in paediatric and adolescent populations |
| PEMOB29 | Selection of cabotegravir dosing regimens for HIV treatment and pre-exposure prophylaxis (PrEP) in adolescents by Leveraging adult data | Poster exhibition | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring in paediatric and adolescent populations |
| EPB172 | Targeted delivery of dolutegravir to HIV reservoirs in the mesenteric lymphatic system by lipophilic ester prodrug approach | E-poster | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring |
| EPB173 | Characterization of the absorption, metabolism, and excretion of islatravir, an HIV nucleoside reverse transcriptase translocation inhibitor, in humans | E-poster | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring |